The influence of CRF on testosterone production in primary mouse Leydig cell cultures was studied, and the type of CRF receptor (CRF-R) involved in this activity was determined. CRF directly stimulated testosterone production in mouse Leydig cells, but did not influence the maximum human (h)CG-induced testosterone production. The effect was time-and dose-dependent, saturable with an EC 50 of 2.84 nM for hCRF, antagonized by the CRF antagonist ␣-helical CRF9 -41, and accompanied by intracellular cAMP elevation. The rank order of potency of the natural CRF agonists, hCRF, ovine CRF, sauvagine, and urotensin, corresponded to that of their activities on CRF-R1 in rat pituitary cells and also to that reported for this receptor, but not for CRF-R2, when transfected into various cell lines. Furthermore, the difference in response of mouse Leydig cells to [11-D-Thr,12-D-Phe]-and [13-D-His,14-D-Leu]-ovine CRF corresponded to that measured when COS cells expressing CRF-R1 were activated, but was considerably smaller than that observed for activation of COS cells expressing CRF-R2␣ or -R2␤. The messenger RNA encoding the mouse CRF-R1 was detected by RT-PCR in mouse Leydig cell preparations. In contrast to mouse Leydig cells, CRF agonists had no influence on the basal testosterone and cAMP production by rat Leydig cells, nor did the agonists or antagonist change the hCGstimulated testosterone and cAMP production by these cells. It is concluded that mouse Leydig cells express CRF-R1, mediating elevation of testosterone production by CRF agonists through cAMP. Because potencies of CRF agonists in activating mouse Leydig cells were more than 10-fold lower compared with their potencies in stimulating rat pituitary cells, it is suggested that the coupling of the CRF-R1 to intracellular signaling in Leydig cells is different from that in corticotropic pituitary cells, at least in quantitative terms. (Endocrinology 139: [651][652][653][654][655][656][657][658] 1998) 
C ORTICOTROPIN-RELEASING factor (CRF), a 41-amino acid peptide, was originally isolated from the hypothalamus (1) and was shown to be the principal neuroregulator mediating the hypothalamic-pituitary-adrenocortical stress axis. CRF was later found to be widely distributed also outside the hypothalamus throughout the central nervous system, where it obviously functions as a neurotransmitter or neuromodulator eliciting a wide spectrum of autonomic, electrophysiological, and behavioral effects (for a review see Ref. 2) .
In addition to pituitary and central nervous system effects, some effects of CRF in vitro and in vivo have been found at various peripheral sites, where specific binding sites for CRF or messenger RNA (mRNA) for CRF receptors have been localized as well. Such sites include the immune system (3-6), cardiovascular system (7-10), retina (11) , uterine sites including placenta (12, 13) , and the gonads, ovary (14) , and testis (15) (16) (17) (18) , thereby implicating CRF not only as central mediator of stress responses, but also in a variety of stressrelated or -unrelated peripheral functions.
In 1993, one type of receptor for CRF (CRF-R), now designated CRF-R1, was cloned from several species, including human (19, 20) , rat (21, 22) , and mouse (20) , and shown to be a member of the seven-transmembrane helix receptor family. Recently, the cloning and characterization of two alternatively spliced forms of a novel subtype of CRF-R (CRF-R2) from rat brain were reported (23) . They result in two putative receptor proteins of 411 and 431 amino acids, now designated as CRF-R2␣ and CRF-R2␤, respectively. CRF-R2␣ and CRF-R2␤ have also been cloned from human (24) and mouse (7) (8) (9) , respectively.
In rat central nervous system, CRF-R1 and CRF-R2 mRNA showed different anatomical distribution (25) , as did CRF-R2␣ and CRF-R2␤ (26) . From the two CRF-R2 forms, R2␣ mRNA was found to be primarily expressed in central nervous system while R2␤ mRNA was additionally observed at peripheral sites (26) . On the other hand, CRF-R1, but neither form of CRF-R2, is thought to be present in the rat (23, 25, 26) or mouse pituitary (8) . The heterogeneous distribution patterns of CRF-R1, -R2␣, and -R2␤ mRNA suggest distinct functional roles for each receptor type.
One of the peripheral sites for which a putative function for CRF has been suggested is the Leydig cell of the testis. By one group, the hCG-stimulated testosterone production by the rat Leydig cell was found to be inhibited by CRF through specific receptors for CRF (15, 17) . On the other hand, in mouse Leydig cells CRF directly stimulated the steroid production but did not influence the maximum hCG-stimulated production (18) .
From these results it might be suggested that different types of CRF-R or different coupling to the intracellular signaling occur in the Leydig cells from rat and mouse. Rat cells were found to express, at very low levels, mRNAs of the pituitary form and of two splice variants of the CRF-R1, the pituitary receptor sequence being the predominant (27) . However, in agreement with others (18), we could not find any biological effect of different CRF agonists on the rat cells but found a stimulatory effect on testosterone production by mouse Leydig cells. The aim of this study was to examine, first, the responses of the mouse Leydig cells to CRF peptides and to characterize their pharmacological profiles. This was thought to lead to some conclusion about the type of receptor, because it has been shown that CRF agonists differ in their rank order of potency in binding to (28) , or in stimulation of adenylate cyclase activity (7, 23, 24, 29) in, CRF-R1-and CRF-R2-transfected cells. With this information we then sought to determine the expression of the respective mRNAs in mouse Leydig cell preparations. As a result, we found Leydig cells of mice to respond to CRF peptides corresponding to the specificity of CRF-R1 and to express mRNA for this receptor type.
Materials and Methods

Substances and media
The agonists of the CRF receptor human (h)CRF, ovine (o)CRF, frog sauvagine, carp urotensin I, urocortin, [16-l-Lys]-oCRF, and the antagonist ␣-helical CRF9 -41 were synthesized as previously described (30) . Furthermore, a series of 21 analogs of oCRF, each of them with two neighboring amino acids (position 1,2; 3,4 . . . 39,40; 40,41) systematically substituted by their d-isomers (DD-replacement set), were synthesized. Buserelin was a gift from Hoechst AG (Frankfurt am Main, Germany). hCG with purity Ͼ95% was obtained from Calbiochem (Bad Soden, Germany). Percoll was purchased from Pharmacia (Uppsala, Sweden), MEM was purchased from GIBCO BRL (Eggenstein, Germany). Collagenase type 1A and 3-isobutyl-1-methylxanthine (IBMX) were obtained from Sigma (Deisenhofen, Germany). Earle's salt solution without CaCl 2 was prepared from substances of analytical grade. BSA (fraction V) was from SERVA (Heidelberg, Germany). For the isolation and incubation of the Leydig cells, MEM containing 25 mm HEPES buffer (pH 7.4) and 0.5 g/liter BSA was used. Continuous density gradients of 0 -90% Percoll were prepared with Earle's salt solution containing 1 g/liter BSA and 25 mm HEPES buffer (pH 7.4).
Isolation and purification of Leydig cells
Leydig cells were prepared from NMRI-mice (25-30 g) (31), adult Wistar, Sprague-Dawley, and Fischer rats (ϳ250 g), all of which were supplied by Charles River, Sulzfeld, Germany, and from immature Wistar rats (21 days). The animals were maintained on a 12-h light, 12-h dark cycle, with food and water available ad libitum. The testes of mice were decapsulated, mechanically dispersed in medium, and freed from tubuli and tissue fragments by filtration through gauze. The cells were collected by centrifugation at 800 ϫ g for 15 min at 20 C, resuspended in medium, and layered onto the Percoll gradient. After centrifugation at 1,800 ϫ g for 25 min at 20 C, four bands were obtained; from the third band, highly purified Leydig cells were recovered and washed twice by centrifugation. The cells were identified by their yellow halo under phase-contrast microscope and counted in the Neubauer chamber under microscope. Cells (100,000 or 165,000) in 2 ml incubation medium containing 15 mm NaHCO 3 were plated in 12-well culture plates and allowed to attach to the surface at 37 C under 5% CO 2 /air for 3 h. The testes of rats were dispersed using 0.25 mg/ml collagenase in medium for about 20 min in a shaking water bath (100 rpm) at 37 C, after which the Leydig cells were purified as described for mice; however, with immature cells the density gradient centrifugation was omitted. Cells of adult rats (500,000 -1,000,000 cells) and of immature rats (1,000,000 cells) were allowed to attach to the well plates for 2 and 1 h, respectively.
Incubations of Leydig cells with hCG and peptides and determination of testosterone and cAMP
The medium was removed from the attached cells and replaced with 1 ml of fresh incubation medium containing the phosphodiesterase inhibitor IBMX (2.5 mm) and hCG, CRF agonists, the CRF antagonist, the peptides of the DD-replacement set of oCRF, or buserelin at the indicated concentrations. When the CRF antagonist was tested, it was added to the cells 15 min before addition of the CRF agonists. The incubations were performed in a shaking water bath (35 rpm) at 37 C for the indicated times. One hundred microliters of the medium were frozen for the determination of testosterone by RIA (DPC Biermann GmbH, Bad Nauheim, Germany) and 200 l were dried in a Speed Vac and stored frozen for the determination of extracellular cAMP by RIA (Immuno Biological Laboratories, Hamburg, Germany) after acetylation of samples and standards. Intracellular cAMP was determined after the extraction of the cells with 80% (vol/vol) ethanol and drying in a Speed Vac.
ACTH-releasing activity of the peptides of the oCRF DDreplacement set
Pituitary cells were obtained from the anterior pituitary of male Wistar rats and used for determining the ACTH-releasing activities of the CRF peptides as described earlier (10) . The activities of the peptides were determined at the concentration of 0.3 nm, corresponding to the EC 50 value of oCRF, and compared with their activities on mouse Leydig cells at 10 nm peptide on a normalized scale. Additionally, their ACTHreleasing activities were measured at 1 m peptide to ensure that the effect of the peptides of the set further increased and reached the same maximum value as oCRF (data not shown).
cAMP-accumulating activities of CRF analogs on COS cells expressing rCRF-R1, rCRF-R2␣, or rCRF-R2␤
COS-1 cells were transiently transfected by a modified calcium phosphate coprecipitation method (32) . The cells were incubated at 37 C and 5% CO 2 /air for 22 h in 9-cm dishes containing 9 ml DMEM and 30 g plasmid DNA [complementary DNAs (cDNAs) of rCRF-R1, rCRF-R2␣, and rCRF-R2␤ subcloned into pcDNAI, Invitrogen]. Afterward, the cells were trypsinized and seeded into 24-well plates at a density of 100,000 cells per well. Two days after transfection, the cells were washed for 10 min with PBS/0.2 mm IBMX and incubated with different concentrations of [11- 
Data analysis
EC 50 values for the activities of the peptides in stimulating and inhibiting the production of testosterone in Leydig cells were calculated from the concentration-response curves by a four-parameter logistic curve-fitting program. Differences between EC 50 values of the native CRF agonists were assessed by the unpaired Student's t test.
Nested PCR cloning and sequence analysis of a mouse (m)CRF-R1-cDNA segment
Poly(A) ϩ -RNA was isolated from the mouse crude Leydig cell preparation (without purification by gradient centrifugation) by using the Fast track 2.0-Kit (Invitrogen, NV Leek, The Netherlands). First-strand complementary DNA (cDNA) was synthesized using random hexamer primers and Moloney murine leukemia virus-RT (Life Technologies, Eggenstein, Germany). Synthetic oligonucleotides were designed based on segments of the mouse CRF-R1-cDNA (20) . 
Results
Effect of CRF peptides on testosterone production in mouse Leydig cells
hCRF time-(data not shown) and dose-dependently (Fig.  1 ) stimulated the testosterone production of the mouse Leydig cells with EC 50 of 2.84 nm. Within 30 and 60 min, the testosterone production was maximally stimulated by about 13-and 22-fold, respectively, over its basal activity. The CRF antagonist ␣-helical CRF9 -41 did not influence the basal testosterone production ( Fig. 1 ) but dose-dependently inhibited the testosterone production stimulated by hCRF with an IC 50 of 65.0 nm (Fig. 2) . The superactive GnRH agonist buserelin showed no effect on the basal testosterone production (Fig. 1) .
Concentration-response curves of testosterone production evoked by hCG alone or by hCG in the presence of a maximal dosage of CRF showed that CRF did not stimulate additional formation of testosterone in mouse Leydig cells concurrently stimulated with a maximal concentration of hCG (Fig. 3) . The maximum stimulation of testosterone production by CRF within 30 -60 min incubation was about 35% of that elicited by hCG. The antagonist ␣-helical CRF9 -41 had no influence on hCG-induced testosterone (data not shown).
The pharmacological profile of the stimulating effect of natural CRF agonists on the testosterone production is shown in Table 1 , where their EC 50 values are given, together with those for their ACTH-releasing activities on rat pituitary cells as obtained earlier (10) . Urocortin was the most active agonist, whereas hCRF, oCRF, sauvagine, and urotensin had lower but nearly the same activity on both cell types, but the EC 50 values of their activities on mouse Leydig cells were, on average, 16.5-fold higher than on rat pituitary cells (Table 1) . Although the scrotal temperature is some degrees below 37 C, the incubations of Leydig cells were generally performed at 37 C to be compared with data on pituitary cells. When, in one experiment, the testosterone production stimulated by oCRF was compared at 37 C and 25 C, no significant difference in the EC 50 values was found. Figure 4 demonstrates that intracellular cAMP was increased by hCRF at concentrations that also stimulated testosterone production. However, the EC 50 for the CRF-stimulated increase of intracellular cAMP (ϳ50 nm) was about 20 times higher than that for the CRF-stimulated testosterone production.
Effect of the oCRF DD-replacement set on testosterone production in mouse Leydig cells and ACTH release from rat anterior pituitary cells
In Table 2 and Fig. 5 the neighboring positions of the two amino acid residues in the sequence of oCRF that were replaced with their D-isomers are indicated for all 21 analogs synthesized. Their potencies in stimulating the testosterone production in mouse Leydig cells differed widely. Full concentration-response curves in the concentration range up to 1 m were only obtained for one third of the peptides for which the EC 50 values are given in Table 2 . With all other peptides, at least some response was obtained at concentrations up to 1 m. When the activities of the DD-analogs in stimulating the testosterone production of mouse Leydig cells were compared with their activities in the ACTH release from rat pituitary cells, a good correspondence between the two activities was obtained (Fig. 5) . Figure 6D 
Effect of CRF peptides on testosterone production and cAMP in Leydig cells of rats
When adult rat Leydig cells were incubated for 0 -180 min in the absence or presence of hCG and 1 m hCRF, oCRF, sauvagine, urotensin, or ␣-helical CRF9 -41, no influence of the CRF peptides on the basal and hCG-stimulated testosterone production was observed at any time. This was true for cells from Wistar, Fischer, and Sprague-Dawley rats as well as for cells from 21-day-old rats. Furthermore, the peptides did not change the extracellular cAMP. To determine whether only a subpopulation of rat Leydig cells was able to respond to CRF, cells from adult rats were separated into a low-(Ͻ1.07 g/ml) and high-density (Ͼ1.07 g/ml) fraction. The cells in the two fractions strongly differed in their testosterone production, which was stimulated by hCG in the low-density cells only by about 20% of that observed with the high-density cells. However, CRF peptides did not influence the testosterone production stimulated by hCG in either cells. Also in contrast to mouse Leydig cells, the GnRH agonist buserelin was found to acutely stimulate the basal testosterone production of rat cells with an EC 50 value of 0.29 nm.
cAMP-accumulating activities of CRF analogs on COS cells expressing rCRF-R1, rCRF-R2␣, or rCRF-R2␤
From the DD-replacement set, [11- (Fig. 5) . The ratio between their potencies in accumulating cAMP in COS cells expressing the rCRF-R1 (EC 50 0.94 and 0.45 nm, respectively; Fig. 6A ) was found to be very close to that observed in their action on pituitary (Fig. 5 ) and Leydig cells (Fig. 6D) .
However, in COS cells transfected with rCRF-R2␣ or rCRF-R2␤, the analog (Fig. 6A) . [16-l-Lys]-oCRF was earlier shown to possess very low activity in the ACTH release from rat pituitaries (30) and in the present study was found to be nearly equally active on CRF-R1, CRF-R2␣, and CRF-R2␤ expressed in COS cells (EC 50 4.51, 5.11, and 2.71 nm, respectively). Furthermore, nearly the same ratios in the potencies of [11-d- Fig. 6A ) but not CRF-R2␣ or CRF-R2␤ (Fig. 6, B and C) .
Isolation of CRF-R1-cDNA fragment from mouse crude Leydig cell preparation
The second round of PCR amplification of CRF-R1-cDNA obtained from poly(A) ϩ -RNA of crude mouse Leydig cells resulted in a single band according to the expected size of 316 bp. After subcloning, the sequence of the PCR product was found to correspond to the bases 247-562 of the mouse CRF-R1-cDNA (20) .
Discussion
Different results have been reported about the in vitro responsiveness of Leydig cells of rats and mice to CRF. The hCG-stimulated testosterone production of the rat cells was reported to be inhibited by a CRF receptor-specific mechanism, whereas the basal production of testosterone and the basal cellular cAMP of rat cells were not changed by CRF (15) . On the other hand, in another study mouse Leydig cells responded directly to CRF by increasing the basal testosterone production and the cAMP concentration but without influencing the hCG-stimulated testosterone (18) . In the same study, no influence of CRF on Leydig cells from rats was found. From these results, especially the different influence of CRF on cAMP in the two cells, it might be suggested that different types of the CRF receptor or different signaling events occur in Leydig cells of different species. Since mRNAs of the pituitary form and of two splice variants of CRF-R1 were detected in rat Leydig cells (27) , the existence of this type of receptor in rat cells appears likely. However, we could not detect any effect of CRF agonists on Leydig cells obtained from rats. The present study was undertaken to determine the type of CRF receptor in mouse Leydig cells by functional and molecular criteria.
In agreement with an earlier report (18) , our results showed that hCRF, which is identical in its amino acid sequence to rat and mouse CRF (34) , directly stimulated the testosterone production in Leydig cells from mice in a timeand dose-dependent manner (Fig. 1) . The effect was saturable ( Fig. 1) , characterized by a low EC 50 of 2.84 nm hCRF (Table 1) , antagonized by the specific CRF antagonist ␣-helical CRF9 -41 (Fig. 2) , and obviously mediated by cAMP ( Fig. 4) . These findings strongly argue for a CRF receptormediated process.
It has been shown that the overall production of steroids in Leydig cells and other steroidogenic cells is controlled by events that facilitate the transport of cholesterol from lipid droplets and other cellular stores to the inner mitochondrial membrane, where the synthesis of the cell-specific steroid is initiated (for a review see Ref. 35 ). Several proteins have been implicated in this cholesterol transfer (35) , regulated by LH/ hCG or other trophic hormone receptors. Since CRF did not increase the testosterone production in the mouse Leydig cell additively to hCG (Fig. 3) , the CRF and hCG signaling pathways probably converge, at the latest, at the step of the cholesterol transfer, but CRF is able to exploit only about one third of the hCG-stimulated capacity (Fig. 3) .
When the specificity of the effect of CRF was studied by testing natural CRF agonists (Table 1) , rat urocortin, together with human urocortin, the latest member of the CRF family (28), was found to possess the highest potency. This agreed with the fact that urocortin, of all CRF agonists, also exhibited the highest activity in the cAMP accumulation by, and highest affinity to, all known types of CRF receptors, i.e. CRF-R1 (28, 36), CRF-R2␣ (36), and CRF-R2␤ (28, 36) , transfected into various cell lines. Furthermore, rat urocortin was most active in the release of ACTH from rat pituitary cells (Refs. 28 and  36 and Table 1 ), which contain almost exclusively CRF-R1 (23) .
The other agonists, hCRF, oCRF, sauvagine, and urotensin, differed only slightly in their potencies in stimulating testosterone production in mouse Leydig cells, as seen from their EC 50 values (Table 1) . This is in line with the specificity of CRF-R1 toward these peptides, as shown with rat pituitaries (Table 1 and Refs. 10, 28, 36, and 37) and cells expressing CRF-R1 (7, 21, 23, 24, 28, 29) . However, cells expressing one of the splice variants of CRF-R2, CRF-R2␣ (23, 24, 29) or CRF-R2␤ (7), accumulated cAMP in response to sauvagine with a potency, i.e. 1/EC 50 , 9-to 40-fold higher as compared with hCRF or oCRF. Similarly, the affinity of sauvagine to both receptors was more than 9-fold (8, 28, 29, 36) higher than that of hCRF and oCRF. Therefore, the specificity of the testosterone-stimulating effect of the natural CRF agonists on mouse Leydig cells (Table 1) was the same as obtained for CRF-R1 and different from that for both variants of CRF-R2.
Two further pharmacological indications for the mouse Leydig cell receptor to be of type 1 were obtained. First, the widely differing activities on the Leydig cell testosterone production of the 21 analogs of oCRF (Table 2) , obtained by systematically replacing two neighboring amino acids with their d-isomers (DD-replacement set), corresponded well with their activities on rat pituitary cells (Fig. 5) . Second, two peptides from the DD-replacement set, [11-d- (Fig. 6 , A-C) as they did in their activities on the Leydig (Fig. 6D ) and pituitary cell (Fig. 5) . This is further underlined by the nearly constant ratios between the potencies of both peptides and the potency of [16-l-Lys]-oCRF in their activities on Leydig cell (Fig. 6D) and on COS cells expressing CRF-R1 (Fig. 6A) , in contrast to cells expressing CRF-R2␣ (Fig. 6B) or CRF-R2␤ (Fig. 6C) .
The identity of the Leydig cell receptor was further confirmed by RT-PCR analysis of the mRNA obtained from a crude Leydig cell preparation. Using primer pairs targeted to the mouse CRF-R1 sequence (20) , the nucleotide sequence of the PCR fragment of 316 bp obtained was found to be identical to the corresponding segment of the mouse CRF-R1 cDNA. Further studies are under way to verify the possible existence of splice variants of this type as has been demonstrated for rat Leydig cells where two minor variants of CRF-R1 cDNA were derived from the cell mRNA (27) .
Taken together, from the pharmacological and molecular data it is concluded that mouse Leydig cells possess CRF receptors of type 1. Remarkably, the CRF antagonist ␣-helical CRF9 -41 showed no partial agonist activity (Figs. 1 and 2) , in contrast to its action on pituitary cells (10, 38) . Furthermore, the potencies of the CRF agonists in their effects on the CRF-R1 in mouse Leydig cells were 10-to 20-fold lower as compared with their effects on the same receptor type in pituitary cells of rat (Table 1 ) and, as reported for CRF (39), of mouse. This was observed with the natural agonists ( Table  1) as well as with the peptides of the DD-replacement set, as shown by their approximately equal activities on the pituitary and Leydig cells at 0.3 and 10 nm peptide concentrations, respectively (Fig. 5) .
Different mechanisms could be operative to explain this difference. The most straightforward possibility is that the affinity of the CRF receptor for the ligands in mouse Leydig and rat pituitary cells might differ. Because the rat and mouse cDNAs encode CRF-R1 proteins that are 98% identical over their full length of 415 amino acids (40), it does not seem very likely that different receptor affinities account for the different potencies. In fact, a survey of the numerous reported studies on CRF binding to the CRF receptors in various tissues and cells of rat and mouse, as well as human, revealed almost identical, species-independent affinities of CRF to its receptors in all tissues with K d values of about 1-4 nm for hCRF and oCRF (4, 10, 41) .
Another possibility would be that more than 90% of the peptides were metabolized during incubations with Leydig cells, which appears to be unlikely to have constantly occurred with all the peptides tested including the CRF analogs of the DD-replacement set. Furthermore, increasing cell numbers and incubation times did not influence their EC 50 values, but increased proportionally the testosterone production. After incubation of hCRF with Leydig cells at cell numbers exceeding by far those normally used, no loss of biological active peptide was observed as assessed by RRA (10) (data not shown). These observations excluded any significant influence of peptide metabolism on the results. Therefore, it is suggested that the coupling of the CRF-R1 to intracellular signaling in Leydig cells is different from that in corticotropic pituitary cells at least in quantitative terms. The EC 50 values of hCRF and oCRF found here for the stimulation of testosterone production in mouse Leydig cells (Table 1) (10) . In conclusion, it is suggested that the stimulation of the testosterone production in mouse Leydig cells by CRF is to a great extent determined stoichiometrically by the fractional occupancy of the receptor. Due to the more than 10-fold higher potency of CRF in activating the same CRF receptor type 1 in pituitary cells from rat and mouse, the coupling of the pituitary receptor to the signaling events in these cells may be more efficient when compared with the mouse Leydig cell. Therefore, the pituitary cell, but not the Leydig cell, might be described as exhibiting spare receptors.
There apparently is also a great disparity in the coupling of the CRF-R1 to cAMP between the mouse Leydig cell and COS cells expressing CRF-R1. The EC 50 (Fig. 6A) and their EC 50 for the stimulation of testosterone production in Leydig cells (ϳ20 nm, Table 2 ). On the basis of these facts it is concluded that among pituitary, Leydig, and COS cells the coupling of CRF-R1 to the signaling cascade is at least in quantitative terms quite different.
It remains unclear why we and others (18) , in contrast to another report (15, 16) , did not find any response of rat Leydig cells to CRF, although various rat strains, adult and 21-day-old rats (this study), and subpopulations of the cells (Ref. 18 and present study) were included in the studies. It may be argued that even slight differences in the isolation procedure for the rat cells could be responsible for different grades of damage to the CRF receptor, while the hCG receptor remains almost intact. Therefore, we looked for possible impairment of another receptor for a short peptide, the GnRH receptor, which was shown to be present and activated in Leydig cells of rats but not of mice (43, 44) . In agreement with the literature, we did not find buserelin, a superactive GnRH agonist, to influence the testosterone production of mouse Leydig cells. However, the high potency response of our preparation of rat Leydig cells to buserelin (EC 50 0.29 nm) confirmed that these cells were of high functional integrity.
In summary, our pharmacological and molecular data provide evidence that mouse Leydig cells express CRF receptors of type 1, the same type occurring in the pituitary. When activated by CRF agonists, the basal testosterone production is stimulated, similar to the pituitary cAMP-mediated, but at seemingly lower cellular coupling efficiency.
